Patents by Inventor William S. Caldwell

William S. Caldwell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10590135
    Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Charles A. Blum, Richard Dana Caldwell, Rebecca Casaubon, Jeremy S. Disch, Ryan Michael Fox, Karsten Koppetsch, William Henry Miller, Pui Yee Ng, Christopher Oalmann, Robert B. Perni, Bruce G. Szczepankiewicz, Brian H. White
  • Publication number: 20100121061
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Application
    Filed: December 8, 2009
    Publication date: May 13, 2010
    Applicant: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 7498770
    Abstract: A load controlled battery charging device is provided which is structured to apply an electrical charge to a plurality of rechargeable storage batteries having a wide range of voltage output capacities. The device includes an electrical charging circuit having an input connection to a power source to provide the power required to permit recharging the batteries. The load controlled charging device also includes a load bank structured to draw a substantially constant electrical current from the power input, and may include a rectifier to convert an alternating current power supply to a direct current to be applied to the rechargeable storage batteries. Additionally, the load controlled battery charging device includes a charging current output connection structured to interconnect the electrical charging circuit to the rechargeable storage battery, at least during the charging operation.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: March 3, 2009
    Assignee: Caldwell-Lazer, Inc.
    Inventor: William S. Caldwell, II
  • Patent number: 7045538
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 22, 2004
    Date of Patent: May 16, 2006
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 6979695
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Grant
    Filed: October 2, 2002
    Date of Patent: December 27, 2005
    Assignee: Targacept, Inc.
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Publication number: 20030125345
    Abstract: The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.
    Type: Application
    Filed: October 2, 2002
    Publication date: July 3, 2003
    Inventors: William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Srishailkumar B. Hadimani, Haeil Park, Jared M. Wagner, Peter A. Crooks, Patrick M. Lippiello, Merouane Bencherif
  • Patent number: 5616707
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-N-methyl-4-[3-(6-methylpyridin)yl]-3-butene-1-amine and N-methyl-4-(3-pyridinyl)-3-butyne-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: April 1, 1997
    Inventors: Peter A. Crooks, William S. Caldwell, Gary M. Dull, Balwinder S. Bhatti, Niranjan M. Deo, Alain Ravard
  • Patent number: 5616716
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds are (E)-4-[3-(5-ethoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-[3-(5-ethoxyrindin)yl]-3-buten-1-amine.
    Type: Grant
    Filed: April 23, 1996
    Date of Patent: April 1, 1997
    Inventors: Gary M. Dull, William S. Caldwell, Craig H. Miller
  • Patent number: 5604231
    Abstract: Patients suffering from or susceptible to an idiopathic chronic inflammatory bowel disease (e.g., ulcerative colitis) are treated with pharmaceutical compositions. Those patients are treated by administration of an effective amount of aryl substituted aliphatic compound, an aryl substituted olefinic amine compound or an aryl substituted acetylenic compound. Exemplary compounds are (E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-N-methyl-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine, (E)-metanicotine, (Z)-metanicotine, N-methyl-(3-pyridinyl)-butane-1-amine, N-methyl-4-(3-pyridinyl)-3-butyne-1-amine and (E)-N-methyl-4 -[3-(6-methylpyrindin)yl]-3-butone-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: February 18, 1997
    Inventors: Carr J. Smith, Patrick M. Lippiello, Merouane Bencherif, William S. Caldwell, Gary M. Dull
  • Patent number: 5597919
    Abstract: Patients susceptible to or suffering from central nervous system disorders are treated by administering an effective amount of an aryl substituted olefinic amine compound. Exemplary compounds are ((E)-4-(5-pyrimidinyl)-3-butene-1-amine, (E)-4-[3-(5-methoxypyridin)yl]-3-butene-1-amine. (E)-N-methyl-4-(5-pyrimidinyl)-3-butene-1-amine and (E)-N-methyl-4-[3 -(5-methoxypyrindin)yl]-3-butene-1-amine.
    Type: Grant
    Filed: January 6, 1995
    Date of Patent: January 28, 1997
    Inventors: Gary M. Dull, William S. Caldwell
  • Patent number: 5583140
    Abstract: Patients susceptible to or suffering from central nervous system disorders (e.g., neurodegenerative diseases including presenile dementia, senile dementia of the Alzheimer's type, and Parkinsonism including Parkinson's disease, and other CNS disorders including attention deficit disorder, schizophrenia and Tourette's syndrome) are treated by administering an effective amount of 2-azabicyclo[2.2.1]hept-5-ene and 2-azabicyclo[2.2.2]oct-5-ene compounds.
    Type: Grant
    Filed: May 17, 1995
    Date of Patent: December 10, 1996
    Inventors: Merouane Bencherif, William S. Caldwell, Gary M. Dull, Patrick M. Lippiello
  • Patent number: 5559124
    Abstract: Compounds such as 2-acetoxymethylquinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: September 24, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5510355
    Abstract: Compounds such as 5-chloronicotine, 5-fluoronornicotine, anabaseine, 5-fluoroanabaseine, 2-acetoxymethylquinuclidine or!2-(3-pyridyl)-quinuclidine are useful as locally acting and highly selective muscle relaxants. Each compound, when administered intravenously, acts to bind to musculoskeletal nicotinic receptor sites in a reversible manner causing transient depolarization, and hence provides for reversible muscle relaxation to a patient during anesthesia.
    Type: Grant
    Filed: September 6, 1994
    Date of Patent: April 23, 1996
    Inventors: Merouane Bencherif, Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5276043
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of certain anabasine compounds, certain unsaturated anabasine compounds or unsaturated nicotine compounds. Exemplary compounds are myosmine and anatabine.
    Type: Grant
    Filed: March 12, 1993
    Date of Patent: January 4, 1994
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5242935
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a nicotine compound. Exemplary nicotine compounds are 5-fluoronicotine, 5-bromonicotine, 4.sup.1 -methylnicotine and 5-methylnicotine.
    Type: Grant
    Filed: March 6, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5242934
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a gamma-nicotine compound.
    Type: Grant
    Filed: March 2, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5242916
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a cytisine compound.
    Type: Grant
    Filed: July 7, 1992
    Date of Patent: September 7, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5232933
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an alpha-nicotine type compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: Patrick M. Lippiello, William S. Caldwell
  • Patent number: 5232932
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of a pseudooxynicotine compound.
    Type: Grant
    Filed: May 21, 1992
    Date of Patent: August 3, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello
  • Patent number: 5227391
    Abstract: Patients suffering from neurodegenerative diseases are treated by administering an effective amount of an (R)-(+)-nicotine compound.
    Type: Grant
    Filed: April 10, 1992
    Date of Patent: July 13, 1993
    Assignee: R. J. Reynolds Tobacco Company
    Inventors: William S. Caldwell, Patrick M. Lippiello